Céline Alloux

539 total citations
9 papers, 164 citations indexed

About

Céline Alloux is a scholar working on Oncology, Epidemiology and Pharmacology. According to data from OpenAlex, Céline Alloux has authored 9 papers receiving a total of 164 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Epidemiology and 2 papers in Pharmacology. Recurrent topics in Céline Alloux's work include CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Nonmelanoma Skin Cancer Studies (3 papers). Céline Alloux is often cited by papers focused on CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Nonmelanoma Skin Cancer Studies (3 papers). Céline Alloux collaborates with scholars based in France. Céline Alloux's co-authors include Gilles Freyer, Florence Ranchon, Benoît You, Catherine Rioufol, Vérane Schwiertz, V. Trillet-Lenoir, Eléna Kiouris, Nicolas Vantard, Thierry Vial and Audrey Nosbaum and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal for Quality in Health Care.

In The Last Decade

Céline Alloux

9 papers receiving 163 citations

Peers

Céline Alloux

ONCOL

EPIDE

DERMA

PHARM

GG

Eléna Kiouris France

Randy L. Moore United States

María José Martínez Bautista Spain

Dechun Jiang China

Matthew T. Taylor United States

Marco Tuccori Italy

Nikhil Khandelwal United States

Pansu Chumworathayi Thailand

Jean Regina Switzerland

Sepideh Babaniamansour Iran

Eléna Kiouris France

Céline Alloux

27 ×0.4

ONCOL

8 ×0.2

EPIDE

18 ×0.5

DERMA

28 ×0.9

PHARM

27 ×1.0

GG

Citations per year, relative to Céline Alloux Céline Alloux (= 1×) peers Eléna Kiouris

Countries citing papers authored by Céline Alloux

Since Specialization

Citations

This map shows the geographic impact of Céline Alloux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Alloux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Alloux more than expected).

Fields of papers citing papers by Céline Alloux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Alloux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Alloux. The network helps show where Céline Alloux may publish in the future.

Co-authorship network of co-authors of Céline Alloux

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Alloux. A scholar is included among the top collaborators of Céline Alloux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Alloux. Céline Alloux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Maubec, E., Marouane Boubaya, Lydia Deschamps, et al.. (2023). 1139P Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs). Annals of Oncology. 34. S682–S683. 1 indexed citations

2.

Goutelle, Sylvain, Céline Alloux, Laurent Bourguignon, et al.. (2021). To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models. Therapeutic Drug Monitoring. 43(4). 461–471. 3 indexed citations

3.

Maubec, E., Marouane Boubaya, Peter Petrow, et al.. (2019). Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.. Journal of Clinical Oncology. 37(15_suppl). 9547–9547. 16 indexed citations

4.

Maubec, E., Marouane Boubaya, Peter Petrow, et al.. (2018). Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.. Journal of Clinical Oncology. 36(15_suppl). 9534–9534. 21 indexed citations

5.

Maubec, E., Isabelle Scheer-Senyarich, Marouane Boubaya, et al.. (2017). CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 35(15_suppl). TPS9596–TPS9596. 6 indexed citations

6.

Schwiertz, Vérane, Céline Alloux, Nicolas Vantard, et al.. (2016). SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study. International Journal for Quality in Health Care. 28(3). 311–315. 7 indexed citations

7.

Vantard, Nicolas, Florence Ranchon, Vérane Schwiertz, et al.. (2015). EPICC study: evaluation of pharmaceutical intervention in cancer care. Journal of Clinical Pharmacy and Therapeutics. 40(2). 196–203. 26 indexed citations

8.

Ranchon, Florence, Audrey Nosbaum, Benoît You, et al.. (2014). Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacology and Toxicology. 15(1). 1–1. 70 indexed citations

9.

Ranchon, Florence, Nicolas Vantard, Vérane Schwiertz, et al.. (2014). SIMMEON-Prep study: SIMulation of Medication Errors in ONcology: prevention of antineoplastic preparation errors. Journal of Clinical Pharmacy and Therapeutics. 40(1). 55–62. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact